U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H32O4S
Molecular Weight 416.573
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPIRONOLACTONE

SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

InChIKey=LXMSZDCAJNLERA-ZHYRCANASA-N
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H32O4S
Molecular Weight 416.573
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012151s072lbl.pdf

Spironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with other diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Spironolactone is used primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome.

CNS Activity

Originator

Approval Year

1960
105
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 11.0 nM [IC50]
Antagonist
2849
 120.0 nM [IC50]
Antagonist
2849
 650.0 nM [IC50]
Antagonist
2849
 1.4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

1960
Primary
Approved
8583
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

1960
Primary
Approved
8583
ALDACTONE

Approved Use

ALDACTONE (spironolactone) is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. ALDACTONE is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. ALDACTONE is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension ALDACTONE is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. ALDACTONE is also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy.

Launch Date

1960
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18488807
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
150.41 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18488807
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.37 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18488807
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SPIRONOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf
unknown
 SPIRONOLACTONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf
unknown
 SPIRONOLACTONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A
142
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A
317
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9241
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9241
ChemicalBook
CB9743463
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9743463
eMolecules
29702936
https://www.emolecules.com/cgi-bin/more?vid=29702936
eMolecules
31590111
https://www.emolecules.com/cgi-bin/more?vid=31590111
eMolecules
594297
https://www.emolecules.com/cgi-bin/more?vid=594297
MolPort
MolPort-033-355-721
https://www.molport.com/shop/molecule-link/MolPort-033-355-721
Selleck Chemicals
spironolactone
http://www.selleckchem.com/products/spironolactone.html
ZINC
ZINC000003861599
http://zinc15.docking.org/substances/ZINC000003861599
PubMed

PubMed

TitleDatePubMed
Effect of a selective aldosterone receptor antagonist in myocardial infarction.
2001-08
Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes.
2001-07-10
Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone.
2001-07-01
Genotype/phenotype observations in African Americans with Bartter syndrome.
2001-07
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
2001-07
Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone.
2001-07
Primary aldosteronism: a practical approach to diagnosis and treatment.
2001-06-21
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.
2001-06-01
Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells.
2001-06-01
Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome.
2001-06
Disappearance of spironolactone-induced gynecomastia with triamteren.
2001-06
Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry.
2001-06
[Evidence based medical treatment of heart failure].
2001-06
Guidelines for management of patients with chronic heart failure in Australia.
2001-05-07
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
2001-05-05
Adrenocorticosteroid receptor blockade and excitotoxic challenge regulate adrenocorticosteroid receptor mRNA levels in hippocampus.
2001-05-01
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
2001-05
[Secondary hypertension].
2001-05
Diane 35 and spironolactone combination in the treatment of hirsutism.
2001-05
Breed and heterotic effects on postweaning traits in Altex and New Zealand White straightbred and crossbred rabbits.
2001-05
Effects of canrenone on aorta and right ventricle of the rat.
2001-05
The spironolactone renaissance.
2001-05
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
2001-05
Antimineralocorticoid 11beta-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study.
2001-05
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
2001-04-15
Reducing readmissions for congestive heart failure.
2001-04-15
[What is the role of hormonal treatments in acne?].
2001-04
Aldosteronoma in a dog with polyuria as the leading symptom.
2001-04
Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis.
2001-04
Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint.
2001-04
Factors influencing the prediction of steady state concentrations of digoxin.
2001-04
[Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
2001-03
High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
2001-03
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs.
2001-03
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
2001-03
[Effect of aldosterone on the secretion of endothelin by ventricular fibroblasts].
2001-02
A very short synthesis of steroids from 1,3-butadiene and benzocyclobutenes.
2001-01-12
[Cosmetics--European Parliament demands marketing prohibition].
2001
[Animal experimentation and animal rights. Evangelical Academy Bad Boll, March 23-25, 2001].
2001
[Symposium "The dignity of animals--significance in the enrichment of human life". Basle, March 15-16, 2001].
2001
[White Paper of the Commission of European Community--strategy for a future chemicals policy].
2001
[Permanent embryonic mouse germ cell-lines, an in vitro alternative to in vivo germ cell mutagenicity tests].
2001
Prediction of embryotoxic effects of valproic acid-derivatives with molecular in vitro methods.
2001
[In vitro methods for phototoxicity and photocarcinogenicity testing of drugs].
2001
[Report on the ICCVAM workshop on in vitro methods for assessing acute systemic toxicity].
2001
Internet laboratory for predicting harmful effects triggered by drugs and chemicals. Concept and call for co-operation.
2001
[Replacement of the pyrogen-test as batch control test for the biological substances aprotinin and urokinase].
2001
Reconstructed skin equivalents for assessing percutaneous drug absorption from pharmaceutical formulations.
2001
The suitability of hepatocyte culture models to study various aspects of drug metabolism.
2001
A risk-benefit assessment of pharmacological therapies for hirsutism.
2001
Patents

Patents

JP2002511415A
7
JP2007518689A
11
JP2011510003A
50
JP2011528275A
456
JP4729259B2
38
JP4818354B2
2
JPH0395120A
1
JPH06157968A
1
JPH06157969A
2
JPS54145647A
1
JPS5488254A
1
JPS5821694A
1
JPS6284014A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Edema 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hypertension 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hypokalemia 25 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Primary Hyperaldosteronism Diagnosis 100 to 400 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Hirsutism 50 to 200 mg/day orally in 1 or 2 divided doses. Usual Adult Dose for Congestive Heart Failure 25 mg/day orally. Increase or decrease based on response and evidence of hyperkalemia. Usual Adult Dose for Primary Hyperaldosteronism Initial dose: 100 mg orally once a day. This dosage may be divided into two daily doses, and increased as tolerated every two to three days to a maximum recommended total daily dose of 400 mg.
Route of Administration: Oral
In Vitro Use Guide
Spironolactone (10 uM) abrogated MR agonist aldosterone-increased I (CaL) density in adult rat ventricular myocytes
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:33:25 GMT 2025
Edited
by admin
on Wed Apr 02 08:33:25 GMT 2025
Record UNII
27O7W4T232
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SPIRONOLACTONE
EP   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   INCI  
Official Name English
ALDACTAZIDE COMPONENT SPIRONOLACTONE
Preferred Name English
SPIRONOLACTONE [MART.]
Common Name English
VEROSPIRONE
Common Name English
17-Hydroxy-7?-mercapto-3-oxo-17?-pregn-4-ene-21-carboxylic acid, ?-lactone acetate
Common Name English
SPIRONOLACTONE CEVA
Brand Name English
SPIRONOLACTONE [IARC]
Common Name English
ALDACTONE
Brand Name English
SPIRONOLACTONUM [WHO-IP LATIN]
Common Name English
Spironolactone [WHO-DD]
Common Name English
SPIRONOLACTONE [JAN]
Common Name English
SPIRONOLACTONE COMPONENT CARDALIS
Common Name English
SPIRONOLACTONE [USP MONOGRAPH]
Common Name English
SPIRONOLACTONE [WHO-IP]
Common Name English
NSC-150399
Code English
CARDALIS COMPONENT SPIRONOLACTONE
Brand Name English
SPIRONOLACTONE [ORANGE BOOK]
Common Name English
SPIRONOLACTONE [USP-RS]
Common Name English
spironolactone [INN]
Common Name English
SPIRONOLACTONE [MI]
Common Name English
SPIRONOLACTONE [EMA EPAR VETERINARY]
Common Name English
SPIRONOLACTONE [VANDF]
Common Name English
PREGN-4-ENE-21-CARBOXYLIC ACID, 7-(ACETYLTHIO)-17-HYDROXY-3-OXO-,.GAMMA.-LACTONE, (7.ALPHA.,17.ALPHA.)-
Common Name English
SPIRONOLACTONE [HSDB]
Common Name English
SC-9420
Code English
SPIRONOLACTONE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 16
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS SPIRONOLACTONE CEVA [AUTHORIZED]
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
NDF-RT N0000011310
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
FDA ORPHAN DRUG 430614
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
IARC Spironolactone
LIVERTOX NBK547921
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
NCI_THESAURUS C49186
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
WHO-ATC C03DA01
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
NDF-RT N0000175557
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS CARDALIS (AUTHORISED)
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
WHO-VATC QC03DA01
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2475
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
DAILYMED
27O7W4T232
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID6034186
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
RS_ITEM_NUM
1619006
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
CAS
52-01-7
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
DRUG BANK
DB00421
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
WIKIPEDIA
SPIRONOLACTONE
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
LACTMED
Spironolactone
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
SMS_ID
100000092408
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
NCI_THESAURUS
C840
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
PUBCHEM
5833
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
HSDB
3184
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
EVMPD
SUB127260
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
ALTERNATIVE
INN
987
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
MESH
D013148
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
CHEBI
9241
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SPIRONOLACTONE
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY Description: A light yellowish white to light yellowish brown powder; odourless or with a faint characteristic odour. Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS. Category: Diuretic. Storage: Spironolactone should be kept in a well-closed container, protected from light. Additional information: Spironolactone may show preliminary melting at about 135?C, followed by resolidification. Definition: Spironolactone contains not less than 97.0% and not more than 101.5% of C24H32O4S, calculated with reference to the dried substance.
EVMPD
SUB10631MIG
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL1393
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
IUPHAR
2875
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
NSC
150399
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-133-6
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
FDA UNII
27O7W4T232
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY
MERCK INDEX
m10157
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY Merck Index
RXCUI
9997
Created by admin on Wed Apr 02 08:33:25 GMT 2025 , Edited by admin on Wed Apr 02 08:33:25 GMT 2025
PRIMARY RxNorm
Related Record Type Details
Structure of Spironolactone H-3
LABELED -> NON-LABELED
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
ANDROGEN RECEPTOR
TARGET->PARTIAL ANTAGONIST
BINDING
MINERALOCORTICOID RECEPTOR
TARGET -> INHIBITOR
Is a prodrug that Inhibits through active metabolites.
Related Record Type Details
Structure of CANRENONE
METABOLITE ACTIVE -> PRODRUG
Structure of 7.ALPHA.-THIOMETHYLSPIRONOLACTONE
METABOLITE ACTIVE -> PRODRUG
MAJOR
PLASMA
Structure of 6.BETA.-HYDROXY-7.ALPHA.-THIOMETHYLSPIROLACTONE
METABOLITE -> PARENT
Structure of 6.BETA.-HYDROXY-7.ALPHA.-THIOMETHYLSPIROLACTONE
METABOLITE ACTIVE -> PRODRUG
The pharmacological activity of spironolactone metabolites in man is not known. However, in the adrenalectomized rat the antimineralocorticoid activities of the metabolites C, TMS, and HTMS, relative to spironolactone, were 1.10, 1.28, and 0.32, respectively.
Structure of 7.ALPHA.-THIOMETHYLSPIRONOLACTONE
METABOLITE ACTIVE -> PRODRUG
Has in vitro activity
Structure of DEACETYLSPIRONOLACTONE
METABOLITE ACTIVE -> PARENT
Structure of DEACETYLSPIRONOLACTONE
METABOLITE -> PARENT
Related Record Type Details
Structure of (2'R)-7ALPHA-(ACETYLTHIO)-5'H-SPIRO(ANDROST-4-ENE-17,2'-FURAN)-3,5'-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.BETA.-HYDROXY-SPIRONOLACTONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (2R)-3,4-DIHYDRO-5H-SPIRO(ANDROST-4-ENE-17,2-FURAN)-3,5-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (2S)-SPIRO(ANDROST-4,6-DIENE-17,2-OXIRAN)-3-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Disulfanyl-spironolactone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 17.ALPHA.-PREGN-4-ENE-21-CARBOXYLIC ACID, 17-HYDROXY-7.BETA.-MERCAPTO-3-OXO-, .GAMMA.-LACTONE, ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of S-(17.ALPHA.-(ETHOXYMETHYL)-17.BETA.-HYDROXY-3-OXOANDROST-4-EN-7.ALPHA.-YL) ETHANETHIOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CANRENONE
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity F by 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of SPIRONOLACTONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966